Centre‐based comparison of double versus single prevention strategy on transfusion‐transmitted cytomegalovirus in at‐risk haemopoietic stem cell transplant patients and a state survey on cytomegalovirus‐seronegative ordering practises
- 2 September 2022
- journal article
- research article
- Published by Wiley in Internal Medicine Journal
- Vol. 53 (5) , 717-722
Abstract
Background Universal leucocyte depletion reduces the risk of transfusion-transmitted cytomegalovirus; however, many clinicians still prescribe cytomegalovirus seronegative units. Aim Our retrospective study aims to confirm the low risk of transfusion-transmitted cytomegalovirus with leucocyte depletion alone and demonstrate the ongoing variability in cytomegalovirus seronegative transfusion prescribing. Methods Over a 9-year period (July 2009-July 2018), occurrences of transfusion transmitted cytomegalovirus in cytomegalovirus seronegative donor/recipient haemopoietic stem cell transplant pairs were compared at one allogeneic haemopoietic stem cell transplant centre providing cytomegalovirus seronegative blood products and leucocyte depletion (double prevention) versus another providing leucocyte depletion only (single prevention). Retrospective chart audit identified patient demographics, blood product exposure and cytomegalovirus infection by polymerase chain reaction. A separate audit examined cytomegalovirus seronegative blood product ordering in a broader range of hospital types. Results We identified 122 and 66 cytomegalovirus-negative donor/recipient haemopoietic stem cell transplant pairs using double and single transfusion prevention strategy respectively. Transfusion exposure to red cells and pooled platelets was similar, although more apheresis platelets were used in the double prevention group. The cytomegalovirus infection rate was 3 (2.4%) and zero in the double and single prevention groups respectively. Cytomegalovirus seronegative unit ordering was not limited to hospitals with obstetric or neonatal populations, suggesting ongoing reliance of cytomegalovirus seronegative units outside this population. Conclusions The analysis suggests a double prevention strategy does not provide additional protection against transfusion-transmitted cytomegalovirus. There is ongoing variability in the acceptance of leucocyte depletion alone despite the low risk of cytomegalovirus infection.Keywords
This publication has 13 references indexed in Scilit:
- Clinical Practice Guidelines From the AABBJAMA, 2016
- Survey of Institutional Policies for Provision of “CMV-Safe” Blood in OntarioAmerican Journal of Clinical Pathology, 2016
- Transfusion in CMV seronegative T‐depleted allogeneic stem cell transplant recipients with CMV‐unselected blood components results in zero CMV transmissions in the era of universal leukocyte reduction: a UK dual centre experienceTransfusion Medicine, 2015
- The residual risk of transfusion‐transmitted cytomegalovirus infection associated with leucodepleted blood componentsVox Sanguinis, 2015
- Is Cytomegalovirus Testing of Blood Products Still Needed for Hematopoietic Stem Cell Transplant Recipients in the Era of Universal Leukoreduction?Transplantation and Cellular Therapy, 2013
- Transmission of cytomegalovirus (CMV) infection by leukoreduced blood products not tested for CMV antibodies: a single‐center prospective study in high‐risk patients undergoing allogeneic hematopoietic stem cell transplantation (CME)Transfusion, 2011
- The natural course of primary cytomegalovirus infection in blood donorsVox Sanguinis, 2010
- Risk of cytomegalovirus transmission by blood products to immunocompromised patients and means for reductionBritish Journal of Haematology, 2004
- Leukocyte Depleted, Unscreened Blood Products Give a Low Risk for CMV Infection and Disease in CMV Seronegative Allogeneic Stem Cell Transplant Recipients with Seronegative Stem Cell DonorsScandinavian Journal of Infectious Diseases, 2002
- A comparison of filtered leukocyte-reduced and cytomegalovirus (CMV) seronegative blood products for the prevention of transfusion- associated CMV infection after marrow transplant [see comments]Blood, 1995